Tuberculosis in the intensive care unit: alternative treatment regimens and association with mortality
Author(s) -
Anton Camila,
Lemos Carolina Xavier,
Machado Felipe Dominguez,
Bernardi Rafaela Manzoni,
Freitas Alana Ambos,
Silva Denise Rossato
Publication year - 2021
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/tmi.13511
Subject(s) - medicine , pyrazinamide , ethambutol , rifampicin , isoniazid , tuberculosis , regimen , retrospective cohort study , surgery , intensive care medicine , pediatrics , pathology
Abstract Objectives Adequate anti‐tuberculosis (TB) treatment is an important factor that can affect the patient's outcome. Higher mortality is found in patients who do not receive optimal treatment that includes isoniazid and rifampicin. The objective of this study is to evaluate the association of use of alternative TB treatment regimens (without rifampicin and isoniazid) and mortality among patients requiring intensive care. Methods Retrospective cohort study, from January 2010 to December 2018. Patients aged > 18 years with a TB diagnosis, admitted to the ICU of a general, tertiary care, university‐affiliated hospital (Hospital de Clínicas de Porto Alegre – HCPA) were included. Data on TB treatment used and outcomes of treatment were collected. Results 462 patients met the inclusion criteria and were included in the analysis; 284 used the usual treatment regimen (rifampicin, isoniazid, pyrazinamide and ethambutol – all orally), and 178 used alternative treatment regimens (IV levofloxacin plus oral ethambutol plus IM streptomycin or IV amikacin, without rifampicin and isoniazid). The mortality was higher among users of alternative treatment regimens (63.5%) than among usual treatment regimen users (51.4%) ( P = 0.011). In a multivariate analysis, age, albumin and death were independently associated with alternative treatment regimens use. Conclusions TB programmes in which IV rifampicin is not widely available should consider including it, especially for critically ill TB patients, for whom there may be improved survival.